Cargando…
Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study
Treatment options for Hepatitis C infection have greatly improved with direct-acting antiviral (DAA) combinations achieving high cure rates. Nevertheless, the cost of this treatment is still high and access to treatment in many countries has been preferentially reserved for patients with more severe...
Autores principales: | Semenova, T., Nemoz, B., Thibault, V., Lagathu, G., Duverlie, G., Brochot, E., Trimoulet, P., Payan, C., Vallet, S., Henquell, C., Chevaliez, S., Bouvier-Alias, M., Maylin, S., Roque-Afonso, A-M., Izquierdo, L., Lunel-Fabiani, F., Marcellin, P., Morand, P., Leroy, V., Larrat, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625182/ https://www.ncbi.nlm.nih.gov/pubmed/31364570 http://dx.doi.org/10.1017/S0950268819001225 |
Ejemplares similares
-
Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma
por: Le Guillou-Guillemette, Hélène, et al.
Publicado: (2017) -
Simeprevir for the treatment of hepatitis C virus infection
por: Izquierdo, Laure, et al.
Publicado: (2014) -
Evaluation of the cobas(®) GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures
por: Némoz, Benjamin, et al.
Publicado: (2018) -
Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice
por: Chevaliez, Stéphane, et al.
Publicado: (2009) -
Evaluation of six commercial SARS-CoV-2 rapid antigen tests in nasopharyngeal swabs: Better knowledge for better patient management?
por: Andreani, Julien, et al.
Publicado: (2021)